Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07041229Enrolling by invitation
Comparing two ways to remove large colon polyps
This trial is for people with large (20-60 mm), non-cancerous colon growths on a wide base. It compares two endoscopic removal methods—ESD and EMR—to see which works best.
MoscowAges 18–100 - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT06693440Recruiting
How PD-1 antibody therapy affects immune function in cancer
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
Zhengzhou, HenanAges 18 years+ - NCT06208917RecruitingPhase 3
Comparing two ways to give ondansetron for chemo nausea in kids
This trial compares two forms of ondansetron (a nausea medicine) — a dissolving film you put in the mouth versus a needle injection — to see which works better in preventing nausea and vomiting caused by chemotherapy in children with solid tumors.
Guangzhou, GuangdongAges 6 months–18 years - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06003621RecruitingPhase 2
Tiragolumab and atezolizumab for advanced solid tumors
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
Albury, New South WalesAges 18 years+ - NCT06169579Enrolling by invitationPhase 1
Trial of ND-003 for advanced solid cancers
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Xiamen, FujianAges 18 years+ - NCT05116579Recruiting
Using blood DNA tests to track PARP inhibitor response
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
Guangzhou, GuangdongAges 18–75 - NCT06927349RecruitingPhase 1
A trial of BA1301 for advanced solid tumors
This trial tests a new drug, BA1301, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if BA1301 can help shrink or control the cancer.
Harbin, HeilongjiangAges 18–75 - NCT06297525RecruitingPhase 1
Testing STP938 for advanced solid tumors
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
St. Petersburg, FloridaAges 18 years+ - NCT05974618Recruiting
Testing an ultrasound model to sort pregnancy ovarian cysts
This study checks how well a specific ultrasound-based scoring tool can tell the difference between harmless (non-cancer) and harmful (cancer) ovarian masses during pregnancy. If you have a cyst or mass that’s at least 5 cm, your scan details may be used to validate the tool.
Leuven, Vlaams-BrabantAges 18–50 - NCT07137312Recruiting
Growing immune cells outside the body to fight cancer
This trial tests a new way to take blood from patients with solid tumors or healthy volunteers, grow immune cells in a lab, and then give them back to potentially treat cancer. It may help people whose standard options have run out.
Jacksonville, FloridaAges 18 years+ - NCT07481799RecruitingPhase 3
Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Zhuhai, GuangdongAges 18–75 - NCT07123129RecruitingPhase 1
Study of SHR-7782 for advanced solid tumors
This trial tests a new drug called SHR-7782 for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+ - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT07165067RecruitingPhase 1
Testing AP601 for advanced solid tumors that have not responded to treatment
This trial tests a new drug called AP601 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and it targets CD73 and CD137 pathways to help your immune system fight cancer.
Waratah, New South WalesAges 18 years+ - NCT05390827Recruiting
Remote digital health data collection for cancer patients
This study collects health data from digital devices (like Apple iPhone or Android) to help researchers understand how physical activity and other measures change during cancer treatment. It may be a way for you to contribute to research from home.
New York, New YorkAges 18 years+ - NCT07098299RecruitingPhase 1
Metformin with chemotherapy or immunotherapy for advanced solid tumors
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Bay City, MichiganAges 18 years+ - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT05985278RecruitingEarly Phase 1
Lutetium-177 catalase injection for advanced solid tumors
This trial tests a new radioactive drug (Lutetium-177 attached to an enzyme called catalase) that is injected directly into tumors. It is for people with advanced solid tumors, like liver, ovarian, or prostate cancer, who have run out of standard treatment options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.